Age-related macular degeneration (AMD) stands as a significant concern in the field of ophthalmology, influencing both the healthcare landscape and the quality of life for the aging population. With a valuation of $9.4 billion in 2022, the AMD market’s trajectory is poised to ascend, projecting a noteworthy valuation of $15.4 billion by 2032, marked by a consistent compound annual growth rate (CAGR) of 5% from 2023 through 2032.
AMD, a progressive ocular ailment, focuses its impact on the macula—a pivotal component of the retina responsible for central vision. As the affliction unfolds, the macular cells experience a gradual deterioration and eventual demise, leading to the deterioration of vision as individuals advance in age. A dual classification categorizes this disease into dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD), each bearing distinct characteristics.
The more prevalent of the two, dry AMD, manifests through the development of diminutive, yellow deposits within the macula. In contrast, wet AMD, while less common, involves the anomalous proliferation of blood vessels beneath the macular region. Dry AMD’s management is often approached through strategic interventions like vitamin supplements and lifestyle adjustments, aimed at mitigating potential risk factors. Conversely, wet AMD necessitates a more intricate approach, characterized by the introduction of medications that are administered via ocular injections. These injections, categorized under the umbrella term “abnormal endothelial growth factor (anti-VEGF) therapy,” perform by obstructing the protein responsible for instigating the growth of aberrant blood vessels.
Key Market Players
- Ionis Pharmaceuticals
- Sanofi S.A.
- Bayer AG
- Coherus Biosciences Inc
- Bausch Health Companies Inc.
- Novartis AG
- Apellis Pharmaceuticals Inc.
- Regeneron Pharmaceuticals Inc.
- F. Hoffmann-La Roche Ltd.
- Biogen
𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐀𝐠𝐞 𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐌𝐚𝐜𝐮𝐥𝐚𝐫 𝐃𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 (𝐀𝐌𝐃) 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐫𝐨𝐰𝐭𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐭: https://www.alliedmarketresearch.com/age-related-macular-degeneration-AMD-market/purchase-options